123 related articles for article (PubMed ID: 32706085)
1. Effective inhibition of tumor in vivo with a novel DNA vaccine targeting chimeric G250.
Li TR; Peng C; Zhong LJ; Jian L; Jian GZ; Jun BX; Hui FL
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7454-7461. PubMed ID: 32706085
[TBL] [Abstract][Full Text] [Related]
2. An enhanced immune response against G250, induced by a heterologous DNA prime‑protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant.
Sun Z; Liu B; Ruan X; Liu Q
Mol Med Rep; 2014 Nov; 10(5):2657-62. PubMed ID: 25190325
[TBL] [Abstract][Full Text] [Related]
3. Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4).
Zhao Y; Wei Z; Yang H; Li X; Wang Q; Wang L; Li S
Biomed Pharmacother; 2017 Jun; 90():147-152. PubMed ID: 28351777
[TBL] [Abstract][Full Text] [Related]
4. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
5. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection.
Herbert N; Haferkamp A; Schmitz-Winnenthal HF; Zöller M
J Immunol; 2010 Jul; 185(2):902-16. PubMed ID: 20548033
[TBL] [Abstract][Full Text] [Related]
6. Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8
Chai D; Shan H; Wang G; Zhang Q; Li H; Fang L; Song J; Liu N; Zhang Q; Yao H; Zheng J
Mol Cancer Ther; 2019 Feb; 18(2):323-334. PubMed ID: 30401695
[TBL] [Abstract][Full Text] [Related]
7. A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy.
Duan Y; Zheng J; Han S; Wu Y; Wang Y; Li D; Kong D; Yu Y
J Control Release; 2008 Apr; 127(2):173-9. PubMed ID: 18316136
[TBL] [Abstract][Full Text] [Related]
8. [Prokaryotic expression, purification and antigenicity identification of human renal cell carcinoma-associated antigen G250].
Xiao Y; Gao J; Gao K; Yan J; Zhang L; Wang Y; Xu Y; Wang W; Wang X; Yu J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Mar; 29(3):269-72. PubMed ID: 23643084
[TBL] [Abstract][Full Text] [Related]
9. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.
Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Zatovicova M; Jelenska L; Hulikova A; Ditte P; Ditte Z; Csaderova L; Svastova E; Schmalix W; Boettger V; Bevan P; Pastorek J; Pastorekova S
Int J Oncol; 2014 Dec; 45(6):2455-67. PubMed ID: 25230982
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250.
Grabmaier K; Vissers JL; De Weijert MC; Oosterwijk-Wakka JC; Van Bokhoven A; Brakenhoff RH; Noessner E; Mulders PA; Merkx G; Figdor CG; Adema GJ; Oosterwijk E
Int J Cancer; 2000 Mar; 85(6):865-70. PubMed ID: 10709109
[TBL] [Abstract][Full Text] [Related]
12. [Construction of a recombinant adenovirus expression vector for human renal tumor- associated antigen G250 gene with AdMax system].
Qi H
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1617-20, 1625. PubMed ID: 18819881
[TBL] [Abstract][Full Text] [Related]
13. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells.
Li G; Passebosc-Faure K; Lambert C; Gentil-Perret A; Blanc F; Oosterwijk E; Mosnier JF; Genin C; Tostain J
Clin Cancer Res; 2001 Jan; 7(1):89-92. PubMed ID: 11205923
[TBL] [Abstract][Full Text] [Related]
14. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C
Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924
[TBL] [Abstract][Full Text] [Related]
16. G250: a carbonic anhydrase IX monoclonal antibody.
Lam JS; Pantuck AJ; Belldegrun AS; Figlin RA
Curr Oncol Rep; 2005 Mar; 7(2):109-15. PubMed ID: 15717944
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Ziffels B; Stringhini M; Probst P; Fugmann T; Sturm T; Neri D
Mol Cancer Ther; 2019 Sep; 18(9):1544-1554. PubMed ID: 31213507
[TBL] [Abstract][Full Text] [Related]
18. [Construction of a DNA vaccine against extracellular domain 1-3 of Flk1 and its inhibitory effect on growth of liver cancer cell line H22].
Lu F; Qin ZY; Li YM; Qi YX; Liu YF; Yang WB
Ai Zheng; 2004 Dec; 23(12):1616-21. PubMed ID: 15601548
[TBL] [Abstract][Full Text] [Related]
19. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J
Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
